Prothena Co. PLC (NASDAQ:PRTA) – Research analysts at Oppenheimer issued their Q1 2018 earnings per share (EPS) estimates for shares of Prothena in a note issued to investors on Thursday, Zacks Investment Research reports. Oppenheimer analyst J. Olson anticipates that the biotechnology company will earn ($1.49) per share for the quarter. Oppenheimer has a “Buy” rating and a $70.00 price objective on the stock. Oppenheimer also issued estimates for Prothena’s Q2 2018 earnings at ($1.56) EPS, Q3 2018 earnings at ($1.67) EPS, Q4 2018 earnings at ($1.79) EPS, FY2018 earnings at ($6.51) EPS, FY2019 earnings at ($5.84) EPS, FY2020 earnings at ($2.11) EPS and FY2021 earnings at ($0.33) EPS.
Several other research firms have also recently commented on PRTA. Wedbush cut Prothena from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $75.00 to $55.00 in a research note on Monday, November 20th. BidaskClub raised Prothena from a “strong sell” rating to a “sell” rating in a report on Thursday, January 11th. Cantor Fitzgerald reissued a “buy” rating and issued a $65.00 price objective on shares of Prothena in a report on Sunday, February 4th. Zacks Investment Research lowered Prothena from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, ValuEngine lowered Prothena from a “hold” rating to a “sell” rating in a report on Friday, December 15th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $74.55.
Shares of Prothena (PRTA) traded up $0.07 on Monday, hitting $34.66. The company’s stock had a trading volume of 179,897 shares, compared to its average volume of 483,885. Prothena has a 12 month low of $27.19 and a 12 month high of $70.00. The firm has a market capitalization of $1,346.41, a PE ratio of -8.54 and a beta of 2.79.
Prothena (NASDAQ:PRTA) last posted its quarterly earnings results on Wednesday, February 14th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.48) by $0.24. The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.27 million. Prothena had a negative return on equity of 33.37% and a negative net margin of 556.84%. The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.41) earnings per share.
Large investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company lifted its position in shares of Prothena by 10.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,559 shares of the biotechnology company’s stock valued at $1,545,000 after acquiring an additional 2,664 shares during the last quarter. Parametrica Management Ltd acquired a new stake in shares of Prothena during the 3rd quarter valued at $307,000. Sectoral Asset Management Inc lifted its position in shares of Prothena by 29.7% during the 3rd quarter. Sectoral Asset Management Inc now owns 195,909 shares of the biotechnology company’s stock valued at $12,689,000 after acquiring an additional 44,863 shares during the last quarter. Hood River Capital Management LLC lifted its position in shares of Prothena by 2.2% during the 3rd quarter. Hood River Capital Management LLC now owns 198,276 shares of the biotechnology company’s stock valued at $12,842,000 after acquiring an additional 4,202 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in shares of Prothena by 16.5% during the 3rd quarter. American Century Companies Inc. now owns 23,982 shares of the biotechnology company’s stock valued at $1,553,000 after acquiring an additional 3,398 shares during the last quarter.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.